Peptide Q&A #8 – Peptides for Women, GHK-CU Healing, IGF-1LR3 Cycles

Peptide Q&A #8 – Peptides for Women, GHK-CU Healing, IGF-1LR3 Cycles, NAD Effects & TRT Side Effects

Welcome back, warriors! In this episode of Peptide Q&A, JD Denham and William T. Haas tackle another round of your most pressing questions about hormones, peptides, and real-world use. No fluff. No scripts. Just straight talk from experience.

We cover:

👩 Peptides for Women: Options for toning up without injections, why SLU-P P-332 tabs and NAD+ are a great start

🩹 GHK-CU for Healing: Sub-Q vs near-wound injections, scar care with serum, and why BPC/TB blends speed recovery

💪 IGF-1 LR3 on Cycle: When to run it, how to pair it post-workout, and why 8-week cycles maximize nutrient partitioning

🏋️ CrossFit Stacks: RETA, AOD, Tesamorelin, and HGH for leaning out and endurance plus 5-Amino-1MQ and Cardarine

⚡ NAD Dosing: Why some people don’t “feel” it instantly, how consistency builds results, and the skin-tightening effect

😴 Peptides for Sleep Apnea: RETA’s proven benefits, DSIP for REM sleep, and inflammation control with Thymosin Alpha-1

🧪 TRT Side Effects: Estrogen spikes, gynecomastia, water retention, AI dosing strategies, and managing DHT issues

🦾 Surgery Recovery: JD’s TB-500/BPC protocol + hyperbaric chamber results, and why the right surgeon matters

💉 L-Carnitine Injections: Why insulin pins won’t work, how to draw with bigger gauges, and site rotation tips

🔬 Sermorelin vs Tesamorelin: Effectiveness, libido claims, and why Tesamorelin often outperforms

💡 Whether you’re exploring women’s protocols, managing TRT, or recovering from surgery, this Q&A is packed with straight answers to help you make informed decisions.

⚠️ Reminder: Peptides are amino acid chains. Not steroids. Not shortcuts. Just science that works when paired with discipline.

👉 Got a peptide question for JD and Will? Drop it in the comments for next week’s Q&A.

📌 Subscribe now for weekly deep dives, protocols, and no-fluff education.

You’re a warrior. Act like one.